COX-2, VEGF and tumour angiogenesis
References (71)
- et al.
Inhibition of tumor angio-genesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives
Drug Resist Updat
(2001) - et al.
Fishing for prostanoids: Deciphering the developmental functions of cyclooxygenase derived prostaglandins
Developmental Biol
(2006) - et al.
15-Hydroxy-prostaglandin dehydrogenase is down-regulated in colorectal cancer
J Biol Chem
(2005) - et al.
Protective association of aspirin/NSAIDs and oesophageal cancer: a systematic review and meta-analysis
Gastroenterol
(2003) - et al.
Up-regulation of cyclooxygenase-2 gene expression correlates with tumour angiogenesis in human colorectal cancer
Gastroenterol
(2001) - et al.
Correlation between cyclooxygenase-2 and tumour angiogenesis in non small cell lung cancer
Lung Cancer
(2003) - et al.
Overexpression of cyclooxygenase-2 is sufficient to induce tumourgenesis in transgenic mice
Jour Biol Chem
(2001) - et al.
Suppression of intestinal polyposis in Apc-delta-716 knockout mice
Cell
(1996) - et al.
PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs
Cell
(1999) - et al.
Targeting cyclo-oxygenase-2 in human neoplasia: Rational and promise
Cancer Cell
(2003)
Prostanoids, ornithine decarboxylase and polyamines in primary prevention of familial adenomatous polyposis
Gastroenterol
Angiogenesis — A new target for future therapy
Vascular Pharmacol
Cyclooxygenase regulates angiogenesis induced by colon cancer cells
Cell
Thromboxane A2 regulation of endothelial cell migration, angiogenesis and tumour metastasis
Biochem Biophys Res Commun
PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells
Biochem Biophys Res Commun
Up-regulation of the enzymes involved in prostacyclin synthesis via Ras induces vascular endothelial growth factor
Gastroenterol
Cyclooxygenase-2 inhibitors suppress angiogenesis and growth of gastric cancer xenografts
Biomed Pharm
Vascular endothelial growth factor (VEGF) — A156 induced prostacyclin synthesis requries the activation of VEGF receptor-1 and -2 heterodimer
J Biol Chem
Cancer in Ireland 1994–2005
Vascular endothelial cell growth factor (VEGF) induces cyclooxygenase (COX)-dependant proliferation of endothelial cells (EC) via the VEGF-2 receptor
Faseb J
Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma
Cancer Res
The relationship between cyclooxygenase-2 expression and colorectal cancer
JAMA
Cyclo-oxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention
J Clin Oncol
Nonsteroidal anti-inflammatory drugs and cancer prevention
Ann Review Med
Reduced risk of colorectal cancer among long term users of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs
Epidemiology
Aspirin use and risk of fatal cancer
Cancer Res
Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer
J Natl Cancer Inst
Prostaglandins and cancer
Gut
Antiangiogenic and antitumour activities of cyclooxygenase-2 inhibitors
Cancer Res
Cyclooxygenase-2 expression correlates with tumour neovascu-larization and prognosis in human colorectal carcinoma patients
Clin Cancer Res
Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer
Cancer Res
Cyclooxygenase-2 expression in human pancreatic adenocarcinomas
Carcinogenesis
Increased expression of cyclooxygenase-2 in human pancreatic neoplasia and potential for chemoprevention by cyclooxygenase inhibitors
Cancer
Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by non steroidal anti-inflammatory drugs
Cancer Res
Cited by (102)
Etiologies of Brain Arteriovenous Malformation Recurrence: A Focus on Pediatric Disease
2023, Pediatric NeurologyA review of HER2 overexpression and somatic mutations in cancers
2023, Critical Reviews in Oncology/HematologyThe COX-2 inhibitor NS398 selectively sensitizes hypoxic HeLa cells to ionising radiation by mechanisms both dependent and independent of COX-2
2020, Prostaglandins and Other Lipid MediatorsCitation Excerpt :Modalities that reduce normal tissue radiosensitivity and/or increase tumour radioresponsiveness are of great interest clinically. The preferential expression of cyclooxygenase (COX)-2 in tumours versus normal tissues makes it a bona fide pharmacological target for anti-cancer treatment [4]. COX is the enzyme responsible for the conversion of arachidonic acid to prostaglandins.
COX-2 Inhibition mediated anti-angiogenic activatable prodrug potentiates cancer therapy in preclinical models
2018, BiomaterialsCitation Excerpt :It plays a critical role in initiation and resolution of inflammation [9]. Enhanced COX-2 expression in different cancer types resulted in elevated levels of proangiogenic factors, like VEGF, leading to tumor progression through elevated angiogenesis [10,11]. Additionally, increased level of COX-2 derived PEG2 can stimulate tumor cell proliferation, motility while inhibiting apoptosis through several tumor-permissive factors like increased angiogenesis and impaired immunosurveillance [12].